Clinical Trial

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Protocol Amendment History 1 change
notable Trial sites expanded: 116 -> 141 locations 2026-07-09
Trial Details
NCT Number NCT05500222
Lead Sponsor Madrigal Pharmaceuticals, Inc.
Conditions NASH, Cirrhosis, Liver
Enrollment 845 participants
Start Date 2022-08-26
Primary Completion 2026-12 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-08